At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics; Osteoporosis therapies
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Coronary artery restenosis; Postmenopausal osteoporosis
Most Recent Events
- 21 Sep 2001 No-Development-Reported for Cancer in USA (PO)
- 21 Sep 2001 No-Development-Reported for Coronary artery restenosis in USA (PO)
- 21 Sep 2001 No-Development-Reported for Postmenopausal osteoporosis in USA (PO)